Manko Joseph M. Jr.

About Manko Joseph M. Jr.

Joseph M. Manko Jr. is a U.S.-based corporate director and investment professional with a background spanning asset management, investment banking, private equity, and corporate finance. His most notable recent role is Lead Director of KORU Medical Systems, Inc., where he has served on the board since 2016 and as Lead Director since 2018. Public filings also show that he serves as a director and, in recent disclosures, chairman of Safeguard Scientifics, Inc. In addition, he has served on the boards of Wireless Telecom Group, Inc., One Stop Systems, Inc., and Creative Realities, Inc., giving him a broad governance profile across publicly traded companies. ([investors.korumedical.com](https://investors.korumedical.com/corporate-governance/board-of-directors?utm_source=openai)) Professionally, Mr. Manko has more than 20 years of experience across capital markets and investment leadership roles. Since 2013, he has been Senior Principal at Horton Capital Management LLC, the investment manager for the Horton Capital Partners Fund. From 2005 to 2010, he was a Partner and Chief Executive Officer of Switzerland-based BZ Fund Management Limited, where he was responsible for corporate finance, private equity investments, three public equity funds, and the firm’s special situations and event-driven strategies. Earlier in his career, he served as a Managing Director at Deutsche Bank in London and began his investment banking career as a Vice President at Merrill Lynch in Hong Kong. He started as a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom LLP. ([investors.korumedical.com](https://investors.korumedical.com/corporate-governance/board-of-directors?utm_source=openai)) His public profile is strongly associated with governance, capital allocation, and board oversight in healthcare-related and innovation-oriented businesses. At KORU Medical, his Lead Director position suggests responsibility for independent board coordination and governance leadership. Public company disclosures also note that he has served as an advisor to numerous pharmaceutical, biotech, and medtech companies. Across his board work, he appears to bring expertise in financing, special situations, shareholder value creation, and strategic oversight rather than day-to-day operating management. ([investors.korumedical.com](https://investors.korumedical.com/corporate-governance/board-of-directors?utm_source=openai))